NEW YORK – Stilla Technologies announced Tuesday it will partner with ID-Solutions, a French liquid biopsy firm, to commercialize oncology detection kits. Terms of the deal were not disclosed.
The commercialization partnership covers an oncology kit line the firms call Identify, which consist of a range of ready-to-use multiplexed mutation panels that run on the Stilla Naica digital PCR system.